GLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications compared to other diabetes treatments, according to data being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Most patients with thyroid eye disease treated with teprotumumab didn’t require additional treatments nearly 2 years later, according to industry-supported research being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass., and published in the journal Thyroid.
Older women with low bone density are more likely to experience their first hip fracture in their 60s compared to older ages, according to research being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Women experiencing moderate-to-severe vasomotor symptoms face a three times greater risk for metabolic-dysfunction-associated steatotic liver disease (MASLD) compared to those with mild symptom severity, according to research being presented Monday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Men who illicitly used steroids to boost muscle size and physical performance and have stopped in the past year have impaired sexual function compared with men currently using steroids, according to a study being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Almost one out of five breast cancer survivors may experience weight gain of more than 10%, suggests a study presented Monday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass. A number of factors are associated with excessive weight gain, the researchers found.
A new “armored” form of CAR T cell therapy may be able to help patients with non-Hodgkin lymphoma whose cancers do not respond to currently available CAR T cell therapies. The Phase I clinical trial was presented at the 2024 ASCO Annual Meeting.
Medications for type 2 diabetes and obesity known as GLP-1 receptor agonists may lower the risk of acute pancreatitis recurrence in people with obesity and those with type 2 diabetes, according to a study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
People under age 50 have a greater risk for heart attack or stroke if they’ve lived with obesity for 10 years, according to industry-sponsored research being presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Having medical conditions linked to obesity does not impact the total weight loss achieved with the anti-obesity medication tirzepatide, according to an industry-supported study being presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
People who have had type 1 diabetes for more than 50 years without kidney complications may still be at substantial risk for heart disease, despite excellent control of blood pressure, cholesterol and blood sugar levels, according to a study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
A new study led by researchers at the American Cancer Society (ACS) shows increased disparities in survival by health insurance status among individuals newly diagnosed with advanced cancers in the United States following the introduction of immune checkpoint inhibitors (ICIs).
Testosterone appears protective against developing type 2 diabetes in men who are overweight or obese and under age 65, but not in men over that age, according to a study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Semaglutide improved taste sensitivity, changed gene expression in the tongue that’s responsible for taste perception, and changed the brain’s response to sweet tastes, according to research presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
People of color and those who experience social vulnerability are more likely to experience worse glycemic control than their white counterparts, according to research presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Prediabetes increases the risk of dying before age 75, particularly due to heart disease, kidney disease and acute diabetic complications, according to a new study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Children who are sedentary for more than six waking hours a day have a significantly increased risk of severe fatty liver disease and liver cirrhosis by young adulthood, a new study finds. The research findings will be presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass and published in Nature’s npj Gut and Liver.
Health insurance companies often deny coverage for new medications that treat children and teens with obesity and type 2 diabetes, meaning many patients who need treatment are unable to afford it, according to a study presented at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Dana-Farber Cancer Institute researchers are leading 3 separate studies with encouraging results in treating patients with central nervous system (CNS) lymphoma, breast cancer, and glioblastoma. These findings are among more than 80 studies presented at ASCO that are led by Dana-Farber-affiliated researchers.
Researchers from The University of Texas MD Anderson Cancer Center presented positive clinical results from two studies today at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right